patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_284639 | REC_0002401 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 7.5 | 60 | female | 1 | 8 | 5.2 | 6 | osimertinib 80 mg daily | 5.4 | true | MSS | 2026-03-15T05:35:57.436837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664728 | REC_0002402 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 11.3 | 68 | female | 0 | 15 | 4.5 | 7 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:35:57.437073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240049 | REC_0002403 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 7 | 60 | female | 1 | 21 | 5.4 | 6 | sotorasib 960 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:57.437306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185247 | REC_0002404 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.5 | 63 | male | 0 | 46 | 6.5 | 2 | pembrolizumab 200 mg q3w | 16.9 | false | MSS | 2026-03-15T05:35:57.437537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564410 | REC_0002405 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.5 | 72 | female | 1 | 19 | 7.3 | 6 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:35:57.437765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941025 | REC_0002406 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.5 | 71 | male | 2 | 11 | 5.5 | 5 | entrectinib 600 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:57.438042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715769 | REC_0002407 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.3 | 80 | female | 1 | 23 | 5.7 | 4 | entrectinib 600 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:35:57.438282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611754 | REC_0002408 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.8 | 60 | female | 1 | 3 | 6.4 | 4 | pembrolizumab 200 mg q3w | 16.6 | true | MSS | 2026-03-15T05:35:57.438516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507614 | REC_0002409 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 5 | 71 | female | 1 | 18 | 4.6 | 2 | sotorasib 960 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:57.438754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602080 | REC_0002410 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 1.5 | 73 | female | 1 | 65 | 4.7 | 6 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:57.438996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430002 | REC_0002411 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 19.1 | 53 | female | 0 | 14 | 4.2 | 2 | sotorasib 960 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:35:57.439257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504022 | REC_0002412 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.7 | 69 | female | 0 | 27 | 4.4 | 1 | pembrolizumab 200 mg q3w | 27 | true | MSS | 2026-03-15T05:35:57.439504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756703 | REC_0002413 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 15.6 | 70 | female | 1 | 22 | 6.8 | 0 | sotorasib 960 mg daily | 35 | true | MSI-H | 2026-03-15T05:35:57.439745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691924 | REC_0002414 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 19.4 | 66 | female | 1 | 17 | 6.2 | 6 | sotorasib 960 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.439988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562115 | REC_0002415 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.9 | 76 | female | 1 | 27 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:57.440300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999573 | REC_0002416 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 14.1 | 70 | male | 1 | 27 | 7.6 | 0 | osimertinib 80 mg daily | 33.4 | false | MSS | 2026-03-15T05:35:57.440546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791027 | REC_0002417 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 18 | 77 | female | 2 | 18 | 5.2 | 1 | sotorasib 960 mg daily | 22.2 | false | MSS | 2026-03-15T05:35:57.440786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278192 | REC_0002418 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10.4 | 75 | female | 1 | 18 | 4.8 | 2 | alectinib 600 mg BID | 27.6 | true | MSI-H | 2026-03-15T05:35:57.441023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608619 | REC_0002419 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 13.2 | 68 | male | 0 | 20 | 5.2 | 5 | alectinib 600 mg BID | 12.4 | true | MSI-H | 2026-03-15T05:35:57.441362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295779 | REC_0002420 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 15.2 | 83 | female | 1 | 12 | 3.7 | 1 | osimertinib 80 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:35:57.441600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175688 | REC_0002421 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.5 | 62 | male | 0 | 43 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.4 | true | MSS | 2026-03-15T05:35:57.441835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397759 | REC_0002422 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.1 | 74 | male | 2 | 11 | 3.2 | 7 | entrectinib 600 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:57.442070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458721 | REC_0002423 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11 | 61 | female | 1 | 15 | 4.6 | 8 | osimertinib 80 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:57.442307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271053 | REC_0002424 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.7 | 76 | male | 1 | 23 | 7.2 | 1 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.442544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959986 | REC_0002425 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 7.9 | 71 | female | 1 | 17 | 5.3 | 6 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:57.442771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817154 | REC_0002426 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 16 | 71 | female | 2 | 18 | 3.6 | 4 | entrectinib 600 mg daily | 5.5 | true | MSS | 2026-03-15T05:35:57.443008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116510 | REC_0002427 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 8.2 | 56 | female | 0 | 39 | 6.7 | 7 | pembrolizumab 200 mg q3w | 4.4 | false | MSS | 2026-03-15T05:35:57.443240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873208 | REC_0002428 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.8 | 64 | male | 1 | 12 | 3.1 | 4 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:57.443479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186631 | REC_0002429 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 30 | 12.2 | 70 | female | 1 | 15 | 5.8 | 0 | alectinib 600 mg BID | 31.8 | true | MSS | 2026-03-15T05:35:57.443728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593128 | REC_0002430 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 14.3 | 67 | female | 0 | 9 | 7.3 | 1 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.443980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531451 | REC_0002431 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 4.7 | 70 | male | 1 | 5 | 4.5 | 7 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.444393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279939 | REC_0002432 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 15.5 | 67 | female | 1 | 16 | 4.6 | 1 | entrectinib 600 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:57.444763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269590 | REC_0002433 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 8.4 | 71 | female | 1 | 12 | 5.3 | 7 | alectinib 600 mg BID | 17 | false | MSS | 2026-03-15T05:35:57.445011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190428 | REC_0002434 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 9.8 | 60 | male | 1 | 13 | 5.2 | 2 | entrectinib 600 mg daily | 27.2 | true | MSS | 2026-03-15T05:35:57.445249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541584 | REC_0002435 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10 | 67 | male | 1 | 18 | 6.3 | 6 | osimertinib 80 mg daily | 8.8 | true | MSS | 2026-03-15T05:35:57.445491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250786 | REC_0002436 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 13.7 | 72 | female | 2 | 17 | 5 | 1 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.445726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438249 | REC_0002437 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 14.3 | 67 | female | 0 | 17 | 5.7 | 6 | sotorasib 960 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:57.445962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713029 | REC_0002438 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.7 | 76 | female | 3 | 6 | 7.2 | 6 | sotorasib 960 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:57.446197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467095 | REC_0002439 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 12.4 | 63 | female | 0 | 19 | 5.2 | 1 | pembrolizumab 200 mg q3w | 25.6 | true | MSI-H | 2026-03-15T05:35:57.446432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834210 | REC_0002440 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 8.3 | 77 | male | 2 | 24 | 4 | 4 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.446665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307590 | REC_0002441 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9.4 | 63 | female | 1 | 14 | 5.6 | 5 | osimertinib 80 mg daily | 5.1 | false | MSS | 2026-03-15T05:35:57.446897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378292 | REC_0002442 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 4.2 | 85 | female | 2 | 44 | 7.8 | 2 | pembrolizumab 200 mg q3w | 21.4 | true | MSS | 2026-03-15T05:35:57.447132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401433 | REC_0002443 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10.9 | 59 | male | 1 | 12 | 4.6 | 3 | entrectinib 600 mg daily | 16.7 | true | MSI-H | 2026-03-15T05:35:57.447373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696333 | REC_0002444 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.5 | 70 | male | 1 | 22 | 5.8 | 7 | sotorasib 960 mg daily | 4.6 | false | MSS | 2026-03-15T05:35:57.447605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389482 | REC_0002445 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 5.9 | 79 | female | 1 | 13 | 6 | 1 | alectinib 600 mg BID | 16.8 | true | MSS | 2026-03-15T05:35:57.447888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687346 | REC_0002446 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 12.7 | 81 | female | 2 | 8 | 6.2 | 2 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:57.448221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626111 | REC_0002447 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.7 | 61 | male | 1 | 4 | 8 | 7 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:57.448472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550304 | REC_0002448 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.2 | 66 | female | 1 | 14 | 6.5 | 5 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:57.448704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967036 | REC_0002449 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.2 | 90 | female | 2 | 12 | 5 | 5 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:57.448939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359131 | REC_0002450 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.3 | 65 | male | 0 | 12 | 3.9 | 5 | pembrolizumab 200 mg q3w | 16.6 | false | MSS | 2026-03-15T05:35:57.449170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972917 | REC_0002451 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.3 | 82 | female | 1 | 12 | 4.6 | 4 | osimertinib 80 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:35:57.449402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962067 | REC_0002452 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 10.4 | 66 | female | 1 | 17 | 5.9 | 5 | pembrolizumab 200 mg q3w | 15.2 | false | MSS | 2026-03-15T05:35:57.449638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227088 | REC_0002453 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.3 | 61 | male | 1 | 16 | 6 | 3 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:57.449871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287299 | REC_0002454 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12 | 66 | female | 1 | 18 | 6.1 | 4 | osimertinib 80 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:57.450101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193044 | REC_0002455 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.5 | 63 | female | 0 | 7 | 5.6 | 5 | pembrolizumab 200 mg q3w | 17 | false | MSS | 2026-03-15T05:35:57.450333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599630 | REC_0002456 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 11.3 | 72 | female | 2 | 10 | 6 | 6 | pembrolizumab 200 mg q3w | 17.6 | false | MSI-H | 2026-03-15T05:35:57.450563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812858 | REC_0002457 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 18.9 | 68 | male | 1 | 25 | 7 | 4 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:35:57.450798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678671 | REC_0002458 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.9 | 68 | female | 0 | 39 | 6.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:57.451086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669979 | REC_0002459 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 12.4 | 65 | female | 0 | 14 | 6.1 | 2 | sotorasib 960 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:57.451328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814982 | REC_0002460 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 10.8 | 64 | male | 1 | 8 | 8.2 | 0 | osimertinib 80 mg daily | 27.6 | true | MSS | 2026-03-15T05:35:57.451564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971064 | REC_0002461 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 4.8 | 64 | female | 1 | 12 | 6.3 | 1 | pembrolizumab 200 mg q3w | 32.3 | true | MSS | 2026-03-15T05:35:57.451795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645114 | REC_0002462 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 3.9 | 55 | female | 1 | 20 | 5.3 | 2 | sotorasib 960 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.452026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480589 | REC_0002463 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 4.4 | 78 | female | 1 | 41 | 7 | 9 | carboplatin + paclitaxel + pembrolizumab | 5.6 | false | MSS | 2026-03-15T05:35:57.452306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451447 | REC_0002464 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 13.2 | 84 | female | 0 | 12 | 6.7 | 7 | sotorasib 960 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:57.452544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701158 | REC_0002465 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 16 | 14.1 | 51 | female | 0 | 10 | 7.1 | 5 | pembrolizumab 200 mg q3w | 10.4 | false | MSS | 2026-03-15T05:35:57.452779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833735 | REC_0002466 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.7 | 68 | female | 0 | 10 | 5.6 | 6 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.453011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743595 | REC_0002467 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 9.7 | 76 | female | 2 | 13 | 5.4 | 1 | osimertinib 80 mg daily | 24.4 | true | MSS | 2026-03-15T05:35:57.453238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556484 | REC_0002468 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.5 | 79 | female | 2 | 45 | 4.1 | 6 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:35:57.453466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422996 | REC_0002469 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.1 | 56 | male | 1 | 6 | 5.2 | 1 | entrectinib 600 mg daily | 29.8 | false | MSS | 2026-03-15T05:35:57.453698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372695 | REC_0002470 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 9.7 | 71 | female | 2 | 16 | 3.9 | 6 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.453927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154787 | REC_0002471 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.6 | 68 | female | 0 | 46 | 7 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:57.454200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872440 | REC_0002472 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 6.3 | 73 | female | 2 | 11 | 4.5 | 6 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:57.454433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194688 | REC_0002473 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 14 | 71 | male | 1 | 14 | 4.8 | 1 | pembrolizumab 200 mg q3w | 25.2 | false | MSI-H | 2026-03-15T05:35:57.454673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843227 | REC_0002474 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 12.8 | 63 | female | 1 | 10 | 4.6 | 5 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:57.454907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606132 | REC_0002475 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 3.2 | 64 | male | 0 | 56 | 5.3 | 5 | pembrolizumab 200 mg q3w | 10.3 | true | MSS | 2026-03-15T05:35:57.455136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521817 | REC_0002476 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 37 | 6.7 | 75 | female | 0 | 38 | 7.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:35:57.455368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912628 | REC_0002477 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.2 | 68 | female | 1 | 15 | 5 | 2 | sotorasib 960 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:57.455602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283414 | REC_0002478 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.7 | 65 | female | 1 | 84 | 7.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:35:57.455833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944760 | REC_0002479 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.6 | 78 | male | 1 | 10 | 4.1 | 5 | osimertinib 80 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:57.456069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957595 | REC_0002480 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 11.6 | 67 | female | 1 | 22 | 3.8 | 3 | alectinib 600 mg BID | 6.9 | true | MSS | 2026-03-15T05:35:57.456401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637118 | REC_0002481 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 11.5 | 57 | male | 1 | 17 | 4.3 | 1 | sotorasib 960 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:57.456642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687859 | REC_0002482 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 5.7 | 72 | female | 3 | 59 | 4.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:35:57.456871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738914 | REC_0002483 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 12.5 | 60 | male | 0 | 12 | 5 | 2 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:35:57.457107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301606 | REC_0002484 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 17.7 | 54 | female | 0 | 25 | 6.8 | 3 | alectinib 600 mg BID | 9.1 | true | MSI-H | 2026-03-15T05:35:57.457389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992849 | REC_0002485 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 36 | 6.6 | 71 | female | 1 | 43 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.8 | true | MSS | 2026-03-15T05:35:57.457625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213951 | REC_0002486 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 7.9 | 72 | male | 1 | 17 | 5.8 | 0 | osimertinib 80 mg daily | 45.2 | false | MSS | 2026-03-15T05:35:57.457863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235033 | REC_0002487 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 12.8 | 68 | female | 0 | 27 | 4.9 | 1 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:35:57.458096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312191 | REC_0002488 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 23 | 9.4 | 77 | female | 1 | 74 | 7 | 0 | pembrolizumab 200 mg q3w | 32.2 | false | MSS | 2026-03-15T05:35:57.458324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822681 | REC_0002489 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 14.9 | 69 | female | 0 | 16 | 5.7 | 3 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:57.458558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468123 | REC_0002490 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 7.2 | 58 | male | 1 | 27 | 4.8 | 5 | osimertinib 80 mg daily | 17.9 | false | MSS | 2026-03-15T05:35:57.458798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567700 | REC_0002491 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.1 | 48 | male | 0 | 35 | 5.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:35:57.459047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593238 | REC_0002492 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 5.2 | 66 | female | 1 | 15 | 7.6 | 5 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:57.459295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383749 | REC_0002493 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 8.3 | 78 | female | 1 | 32 | 3.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.3 | false | MSS | 2026-03-15T05:35:57.459544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493689 | REC_0002494 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 5.4 | 75 | female | 1 | 14 | 6 | 6 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.459796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431171 | REC_0002495 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 19 | 6 | 69 | female | 0 | 53 | 7.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 55.8 | true | MSS | 2026-03-15T05:35:57.460030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233897 | REC_0002496 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.8 | 73 | male | 1 | 58 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:35:57.460355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941041 | REC_0002497 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12 | 66 | female | 0 | 24 | 5.2 | 6 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.460716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135949 | REC_0002498 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.6 | 72 | female | 1 | 15 | 5.7 | 5 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:57.460955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448575 | REC_0002499 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.7 | 66 | female | 1 | 45 | 6.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 5.8 | false | MSS | 2026-03-15T05:35:57.461192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626714 | REC_0002500 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 17.1 | 63 | male | 1 | 4 | 7.5 | 4 | sotorasib 960 mg daily | 23.4 | true | MSI-H | 2026-03-15T05:35:57.461432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.